Sabine M J Welten1, Rob C M de Jong1, Anouk Wezel2, Margreet R de Vries1, Martin C Boonstra3, Laura Parma3, J Wouter Jukema4, Tetje C van der Sluis5, Ramon Arens5, Ilze Bot6, Sudhir Agrawal7, Paul H A Quax1, A Yaël Nossent8. 1. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands. 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Division of Biopharmaceutics, LACDR, Leiden University, Leiden, The Netherlands. 3. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands. 4. Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands. 5. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands. 6. Division of Biopharmaceutics, LACDR, Leiden University, Leiden, The Netherlands. 7. Idera Pharmaceuticals, Boston, MA, USA. 8. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; Einthoven Laboratory for Experimental Vascular Medicine, Leiden University Medical Center, Leiden, The Netherlands. Electronic address: a.y.nossent@lumc.nl.
Abstract
BACKGROUND AND AIMS: We aimed at investigating the role of 14q32 microRNAs in intimal hyperplasia and accelerated atherosclerosis; two major contributors to restenosis. Restenosis occurs regularly in patients treated for coronary artery disease and peripheral arterial disease. We have previously shown that inhibition of 14q32 microRNAs leads to increased post-ischemic neovascularization, and microRNA miR-494 also decreased atherosclerosis, while increasing plaque stability. We hypothesized that 14q32 microRNA inhibition has beneficial effects on intimal hyperplasia, as well as accelerated atherosclerosis. METHODS: Non-constrictive cuffs were placed around both femoral arteries of C57BL/6J mice to induce intimal hyperplasia. Accelerated atherosclerotic plaque formation was induced in hypercholesterolemic ApoE-/- mice by placing semi-constrictive collars around both carotid arteries. 14q32 microRNAs miR-329, miR-494 and miR-495 were inhibited in vivo using Gene Silencing Oligonucleotides (GSOs). RESULTS: GSO-495 administration led to a 32% reduction of intimal hyperplasia. Moreover, the number of macrophages in the arterial wall of mice treated with GSO-495 was reduced by 55%. Inhibition of miR-329 and miR-494 had less profound effects on intimal hyperplasia. GSO-495 administration also decreased atherosclerotic plaque formation by 52% and plaques of GSO-495 treated animals showed a more stable phenotype. Finally, cholesterol levels were also decreased in GSO-495 treated animals, via reduction of the VLDL-fraction. CONCLUSIONS: GSO-495 administration decreased our primary outcomes, namely intimal hyperplasia, and accelerated atherosclerosis. GSO-495 administration also favourably affected multiple secondary outcomes, including macrophage influx, plaque stability and total plasma cholesterol levels. We conclude that 14q32 microRNA miR-495 is a promising target for prevention of restenosis.
BACKGROUND AND AIMS: We aimed at investigating the role of 14q32 microRNAs in intimal hyperplasia and accelerated atherosclerosis; two major contributors to restenosis. Restenosis occurs regularly in patients treated for coronary artery disease and peripheral arterial disease. We have previously shown that inhibition of 14q32 microRNAs leads to increased post-ischemic neovascularization, and microRNA miR-494 also decreased atherosclerosis, while increasing plaque stability. We hypothesized that 14q32 microRNA inhibition has beneficial effects on intimal hyperplasia, as well as accelerated atherosclerosis. METHODS: Non-constrictive cuffs were placed around both femoral arteries of C57BL/6J mice to induce intimal hyperplasia. Accelerated atherosclerotic plaque formation was induced in hypercholesterolemic ApoE-/- mice by placing semi-constrictive collars around both carotid arteries. 14q32 microRNAs miR-329, miR-494 and miR-495 were inhibited in vivo using Gene Silencing Oligonucleotides (GSOs). RESULTS:GSO-495 administration led to a 32% reduction of intimal hyperplasia. Moreover, the number of macrophages in the arterial wall of mice treated with GSO-495 was reduced by 55%. Inhibition of miR-329 and miR-494 had less profound effects on intimal hyperplasia. GSO-495 administration also decreased atherosclerotic plaque formation by 52% and plaques of GSO-495 treated animals showed a more stable phenotype. Finally, cholesterol levels were also decreased in GSO-495 treated animals, via reduction of the VLDL-fraction. CONCLUSIONS:GSO-495 administration decreased our primary outcomes, namely intimal hyperplasia, and accelerated atherosclerosis. GSO-495 administration also favourably affected multiple secondary outcomes, including macrophage influx, plaque stability and total plasma cholesterol levels. We conclude that 14q32 microRNA miR-495 is a promising target for prevention of restenosis.
Authors: Eva van Ingen; Daphne A L van den Homberg; M Leontien van der Bent; Hailiang Mei; Nikolina Papac-Milicevic; Veerle Kremer; Reinier A Boon; Paul H A Quax; Johann Wojta; A Yaël Nossent Journal: Hum Mol Genet Date: 2022-03-31 Impact factor: 6.150
Authors: Eveline A C Goossens; Margreet R de Vries; J Wouter Jukema; Paul H A Quax; A Yaël Nossent Journal: Int J Mol Sci Date: 2020-05-15 Impact factor: 5.923
Authors: Kjell E J Håkansson; Ove Sollie; Karin H Simons; Paul H A Quax; Jørgen Jensen; A Yaël Nossent Journal: Front Physiol Date: 2018-08-22 Impact factor: 4.566
Authors: Reginald V C T van der Kwast; Laura Parma; M Leontien van der Bent; Eva van Ingen; Fabiana Baganha; Hendrika A B Peters; Eveline A C Goossens; Karin H Simons; Meindert Palmen; Margreet R de Vries; Paul H A Quax; A Yaël Nossent Journal: Mol Ther Nucleic Acids Date: 2020-07-21 Impact factor: 8.886